Novel prognostic predictor of haemoglobin–platelet index in diffuse large B‐cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL‐6 production in lymphoma cells. (22nd April 2022)

• Record Type: Journal Article
• Authors: Taniguchi, Takahide; Nakayama, Shoko; Tanaka, Hirokazu; Rai, Shinya; Hirase, Chikara; Morita, Yasuyoshi; Tatsumi, Yoichi; Ashida, Takashi; Matsuda, Mitsuhiro; Hashimoto, Shigeo; Matsumura, Itaru
• Is Part Of: British journal of haematology. Volume 198:Number 2(2022)
• Page Start: 360
• Page End: 372
• Publication Date: 2022-04-22
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.18208
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: We previously reported that a novel haemoglobin–platelet index (HPI) based on anaemia and thrombocytopenia was useful to predict the prognosis of patients with diffuse large B‐cell lymphoma not otherwise specified (DLBCL NOS). Here, we analyse the utility of HPI in a new validation cohort with DLBCL NOS ( n = 94). As a result, we confirm that HPI was effective for differentiating progression‐free survival (PFS) and overall survival in this validation cohort. So, we further compare the utility of HPI with previously reported prognostic markers such as the National Comprehensive Center Network‐International Prognostic Index (NCCN‐IPI), Glasgow prognostic score (GPS), and platelet‐albumin (PA) score, using a larger number of 160 patients consisting of the derivation cohort ( n = 66) and a validation cohort ( n = 94). As a result, the patients with a higher HPI score had significantly worse outcomes, and HPI predicted the prognosis of DLBCL NOS independently of NCCN‐IPI. HPI was more sensitive than GPS and almost the same as PA score in predicting PFS. Moreover, the patients whose lymphoma cells were positive for interleukin‐6 (IL‐6) (75/111 cases) judged by immunohistochemical staining had significantly lower haemoglobin levels and platelet counts than IL‐6‐negative cases (36/111 cases), suggesting the involvement of IL‐6 produced by lymphoma cells in anaemia and thrombocytopenia in DLBCL NOS patients.